Tom Coll

Cooley advised Tentarix Biotherapeutics and three of its subsidiaries on three multiyear collaborations with Gilead Sciences.

Cooley advised Morphimmune, a private biotechnology company, in its definitive merger agreement with Immunome and $125 million private investment.

Cooley advised Red Tree Venture Capital on a $108 million oversubscribed Series B financing – co-led by RA Capital Management – in Bicara Therapeutics, a clinical-stage biotechnology company developing biologics for anti-tumor response.

Cooley represented Wugen, a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies, on its oversubscribed $172 million Series B financing led by Abingworth and Tybourne Capital Management. Partner Tom Coll led the Cooley team.

Cooley represented Bright Peak Therapeutics, a biotechnology company developing next-generation immunotherapies to treat cancer and autoimmune disease, in its $107 million Series B financing led by RA Capital. Partner Tom Coll led the Cooley team.